EPO and chronic kidney disease: In this study, we found that even in patients with chronic renal failure, who had several predispositions for fluctuated HbA1c levels, pretransplant HbA1c was associated with NODAT development; moreover, pretransplant HbA1c levels were an independent predictor of NODAT development in patients receiving no or low-dose EPO.